Markets:

Overview

News

Currencies

International

Treasuries

Emergent BioSolutions Inc. Common Stock (NY:EBS)

7.830 +0.330 (+4.40%)

Streaming Delayed Price Updated: 11:27 AM EDT, Jul 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Emergent BioSolutions Inc. Common Stock

< Previous 1 2

...

12 13 14 15 16 17 18 19 Next >

SHAREHOLDER ALERT: Robbins LLP Announces That Emergent BioSolutions Inc. (EBS) is Being Sued for Misleading Shareholders

April 23, 2021

From Robbins LLP

Via Business Wire

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Emergent BioSolutions Inc. (EBS) Investors

April 23, 2021

From Law Offices of Howard G. Smith

Via Business Wire

JNJ's COVID-19 Vaccine Halt Due To Blood-Clot Concerns To Be Scrutinized Today: WSJ ↗

April 23, 2021

The U.S. is expected to announce its decision on Johnson & Johnson’s (NYSE: JNJ) single-shot COVID-19 vaccine on whether it should be back in circulation...

Via Benzinga

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

April 23, 2021

From The Schall Law Firm

Via Business Wire

Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Lawsuit Filed Against Emergent BioSolutions Inc. (EBS)

April 22, 2021

From Kessler Topaz Meltzer & Check, LLP

Via Business Wire

The Law Offices of Frank R. Cruz Announces Investigation of Emergent BioSolutions Inc. (EBS) on Behalf of Investors

April 22, 2021

From The Law Offices of Frank R. Cruz

Via Business Wire

SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

April 22, 2021

From The Schall Law Firm

Via Business Wire

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

April 22, 2021

Gainers Renalytix AI (NASDAQ:RNLX) shares rose 21.41% to $30.62 during Thursday's regular session. Renalytix AI's stock is trading at a volume of 1.0 million...

Via Benzinga

Topics Artificial Intelligence

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Emergent BioSolutions Inc. (EBS) on Behalf of Investors

April 22, 2021

From Glancy Prongay & Murray LLP

Via Business Wire

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Acadia Pharmaceuticals Inc. (ACAD) on Behalf of Investors

April 22, 2021

From Glancy Prongay & Murray LLP

Via Business Wire

Why Emergent BioSolutions Stock Is Falling Again Today ↗

April 22, 2021

An analyst lowered his price target on the stock.

Via The Motley Fool

Stocks That Hit 52-Week Lows On Thursday ↗

April 22, 2021

On Thursday morning, 5 companies achieved new lows for the year. Interesting Points: Emergent BioSolutions (NYSE:EBS) was the largest, in terms of market cap, to...

Via Benzinga

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Emergent BioSolutions Inc. (EBS) on Behalf of Investors

April 21, 2021

From Law Offices of Howard G. Smith

Via Business Wire

The Daily Biotech Pulse: KemPharm Receives $10M Milestone Payment, Zymergen, Neuropace Debut On Nasdaq, Renalytix Wins US Government Contract, 2 IPOs ↗

April 22, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 21) Alexion Pharmaceuticals,...

Via Benzinga

EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Emergent BioSolutions Inc. Investors with Losses to Secure Counsel Before Important Deadline – EBS

April 21, 2021

From The Rosen Law Firm, P.A.

Via Business Wire

FDA's Inspection Of Emergent's COVID-19 Vaccine Baltimore Plant Outlines Concerns About Sanitary Conditions, Employee Training ↗

April 21, 2021

The FDA concluded its inspection of Emergent BioSolutions Inc’s (NYSE: EBS) troubled vaccine manufacturing plant in Baltimore after it stopped...

Via Benzinga

House Democrats Investigating Emergent BioSolutions' Vaccine Contracts, Call On Execs To Testify ↗

April 21, 2021

A congressional panel has launched an investigation into whether Emergent BioSolutions Inc (NYSE: EBS) was improperly awarded a $628 million federal...

Via Benzinga

The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue ↗

April 21, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 20) Alexion Pharmaceuticals,...

Via Benzinga

EMERGENT BIOSOLUTIONS ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Emergent BioSolutions, Inc. and Encourages Investors to Contact the Firm

April 20, 2021

From Bragar Eagel & Squire, P.C.

Via Business Wire

EMERGENT BIOSOLUTIONS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Emergent Biosolutions Inc. - EBS

April 20, 2021

From Kahn Swick & Foti, LLC

Via Business Wire

EMA Finds Potential Blood Clot Link With JNJ COVID-19 Shot, Adds Safety Warning ↗

April 20, 2021

The European Medicines Agency’s (EMA) safety committee said that the Johnson & Johnson’s (NYSE: JNJ) COVID-19 vaccine has possible links to...

Via Benzinga

Emergent BioSolutions Stock Falls After FDA Initiates Inspection Of Bayview Facility ↗

April 19, 2021

Emergent BioSolutions Inc (NYSE: EBS) has had a tough month: First, the company ruined 15 million doses of Johnson & Johnson’s (NYSE:...

Via Benzinga

Why Emergent BioSolutions Stock Is Tumbling Today ↗

April 19, 2021

The company has halted production of COVID-19 vaccines at its Baltimore facility as an FDA inspection moves forward.

Via The Motley Fool

Why Emergent BioSolutions Stock Fell Today ↗

April 13, 2021

The pause on use of Johnson & Johnson's COVID-19 vaccine had a ripple impact.

Via The Motley Fool

EMERGENT BIOSOLUTIONS ALERT: Bragar Eagel & Squire, P.C. is Investigating Emergent BioSolutions, Inc. on Behalf of Emergent Stockholders and Encourages Investors to Contact the Firm

April 12, 2021

From Bragar Eagel & Squire, P.C.

Via Business Wire

Johnson & Johnson's COVID-19 Vaccine Under Review At EMA For Blood Clots, AstraZeneca Probe Expanded ↗

April 09, 2021

AstraZeneca Plc’s (NASDAQ: AZN) COVID-19 vaccine has recently dominated headlines after cases of rare blood clots were reported in European countries. Now,...

Via Benzinga

Trouble Is Brewing For J&J's Covid Vaccine — What You Need To Know ↗

April 09, 2021

European regulators are investigating four cases of blood clots in recipients of J&J's coronavirus vaccine. In response, JNJ stock dipped Friday.

Via Investor's Business Daily

US Allocates Significantly Lower Number Of J&J Vaccines To States For Next Week: Reuters ↗

April 08, 2021

The U.S. government will allot around 85% less Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccines to states next week, data from the Centers for Disease...

Via Benzinga

Entwistle & Cappucci LLP Investigative Alert: Emergent BioSolutions Inc. (EBS)

April 08, 2021

From Entwistle & Cappucci LLP

Via Business Wire

AstraZeneca Stock Plagued As Issues Continue To Mount For Covid Vaccine ↗

April 07, 2021

AstraZeneca stock dipped Wednesday after European regulators found a possible link between the company's Covid vaccine and rare cases of blood clots.

Via Investor's Business Daily

< Previous 1 2

...

12 13 14 15 16 17 18 19 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.